Article Sidebar
Main Article Content
Abstract
Le MabCampath ou Alemtuzumab est un anticorps monoclonal dirigé contre l’antigène de surface CD52 des lymphocytes. Si son efficacité certaine n’est plus à démontrer dans les Leucémies Lymphoïdes Chroniques (LLC), nous l’avions utilisé en monothérapie sur 2 observations des patients présentant respectivement une LLC à cellule T4 et T8 en première ligne thérapeutique.
Au terme de notre étude, Mr GEN…Jacky est vivant, en rémission complète après 23 mois de suivi. Par contre nous avons déploré le décès de Mme…M-Thérèse au 14ème mois. Elle a rechuté au 12ème mois et est décédée en échappement rapidement évolutif. La tolérance générale est bonne. Nous n’avons pas eu recours ni aux facteurs de croissance, ni aux transfusions sanguines. Cependant il a été observé chez Mr GEN… Jackyune neutropénie fébrile de grade 2 qui est restée inexpliquéeKeywords
Article Details
References
- HALE G, BRIGHT S, CHUMBLEY G, HOANG T, METCALF D, MUNRO AJ, WALDMANN H. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement.Blood 62: 873-82, 1983.
- HALE G, XIA MQ, TIGHE HP, DYER MJS, WALDMANN H. The Campath-1H antigen (CDw52).TissusAntigens 35: 118-27, 1990.
- O’BRIEN SM, KANTARJIAN HM, THOMAS DA, CORTES J, WIERDA WG, KOLLER CA, FERRAJOLI A, BROWNING M, LERNER S, ALBITAR M, KEATING MJ. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.Cancer. 98 (12): 2657-63, 2003.
- PANDOLF F: T-CLL and allied disease: new insights into classification and pathologenesis.DiagImmunol, 4: 61, 1986.
- SUSAN M, O’BRIEN, MARY L, WILLIAMS, STEFAN FARDEL, HAGOP KANTARJIAN, MICHAEL J, KEATING, Campath in refractory hematological malignancies expressing CD-52. A phase II clinical trial of 68 patients.Blood, 98(11): 366A, 2001.
- PAWSON R, DYER M.J.S, BARGE R, MATUTES E, THORNTON P.D, EMMETT E, KLUIN-NLEMANS J.C, FIBBE W.E, WILLIMZE R, and CATOWSKY D. Treatment of T-cell prolymphocytic leukemia with human CD-52 antibody. J ClinOncol, 15 (7): 2667-2672, 1997.
- STEFAN FADERL DEBORAH A, THOMAS, SUSAN O’BRIEN, GUILLERMO GARCIA-MANERO, HAGOP M, KANTARJIAN, FRANCIS J et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood,101(9)::3413-5, 2003.
- DEARDEN CLAIRA E, ESTLLA MATUTES, BRUNO CAZIN et al. High remission rate in T-cell prolymphocytic leukemia with Campath – 1H. Blood 98: 1721-1726, 2001.
- STEVEN L, MCCUNE, JON P, GOCKERMAN, LOSEPH O, MOORE, CARLOS M et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leukemia and Lymphoma, 43 (5): 1007-1011, 2002.
- KEATING M.J, CAZIN B, COUTRE S, BIRHIRAY R, KOVACSOVICS T, LANGER W, LEBER B, MAUGHAN T, RAI K, TJONNFJORD G, BEKKRADA M, ITZHAKI M, and HERAIT P. MabCampath treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J ClinOncol, 20 (1): 205-213, 2002.
- ZHUO ZHANG, MEILI ZHANG, CAROLYN K, GOLDMAN, JEFFREY V, RAVETCH, and WALDMANN T.A. Effective therapy for a murine model of adult T-cell leukemia with the humanized and CD52 monoclonal antibody, MabCampath. Cancer research 63, 6453-6457, 2003.
- CLAIRE DEARDEN. Alemtuzumab in peripheral T-cell malignancies. Cancer Biother Radiopharm. 19(4):391-8, 2004.
- ROWAN W, TITE J, TOPLEY P, and BRETT S.J, Cross-linhing of the MabCampath antigen 5CD-52) mediates growth inhibition in human B-cell and T-lymphoma cell lines, and subsequent emergence of CD-52 deficient cells. Immunology 95: 427-436, 1998.
- KEATING MJ, BYRD J, RAI K, FLINN I, JAIN V, BINET JL et all. Multicenter study of MabCampath in patients with chronic lymphocytic leukemia (B-cell) refractory to fludarabine. Blood 94 (suppl. 1): 705 A, 1999.
References
HALE G, BRIGHT S, CHUMBLEY G, HOANG T, METCALF D, MUNRO AJ, WALDMANN H. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement.Blood 62: 873-82, 1983.
HALE G, XIA MQ, TIGHE HP, DYER MJS, WALDMANN H. The Campath-1H antigen (CDw52).TissusAntigens 35: 118-27, 1990.
O’BRIEN SM, KANTARJIAN HM, THOMAS DA, CORTES J, WIERDA WG, KOLLER CA, FERRAJOLI A, BROWNING M, LERNER S, ALBITAR M, KEATING MJ. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.Cancer. 98 (12): 2657-63, 2003.
PANDOLF F: T-CLL and allied disease: new insights into classification and pathologenesis.DiagImmunol, 4: 61, 1986.
SUSAN M, O’BRIEN, MARY L, WILLIAMS, STEFAN FARDEL, HAGOP KANTARJIAN, MICHAEL J, KEATING, Campath in refractory hematological malignancies expressing CD-52. A phase II clinical trial of 68 patients.Blood, 98(11): 366A, 2001.
PAWSON R, DYER M.J.S, BARGE R, MATUTES E, THORNTON P.D, EMMETT E, KLUIN-NLEMANS J.C, FIBBE W.E, WILLIMZE R, and CATOWSKY D. Treatment of T-cell prolymphocytic leukemia with human CD-52 antibody. J ClinOncol, 15 (7): 2667-2672, 1997.
STEFAN FADERL DEBORAH A, THOMAS, SUSAN O’BRIEN, GUILLERMO GARCIA-MANERO, HAGOP M, KANTARJIAN, FRANCIS J et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood,101(9)::3413-5, 2003.
DEARDEN CLAIRA E, ESTLLA MATUTES, BRUNO CAZIN et al. High remission rate in T-cell prolymphocytic leukemia with Campath – 1H. Blood 98: 1721-1726, 2001.
STEVEN L, MCCUNE, JON P, GOCKERMAN, LOSEPH O, MOORE, CARLOS M et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leukemia and Lymphoma, 43 (5): 1007-1011, 2002.
KEATING M.J, CAZIN B, COUTRE S, BIRHIRAY R, KOVACSOVICS T, LANGER W, LEBER B, MAUGHAN T, RAI K, TJONNFJORD G, BEKKRADA M, ITZHAKI M, and HERAIT P. MabCampath treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J ClinOncol, 20 (1): 205-213, 2002.
ZHUO ZHANG, MEILI ZHANG, CAROLYN K, GOLDMAN, JEFFREY V, RAVETCH, and WALDMANN T.A. Effective therapy for a murine model of adult T-cell leukemia with the humanized and CD52 monoclonal antibody, MabCampath. Cancer research 63, 6453-6457, 2003.
CLAIRE DEARDEN. Alemtuzumab in peripheral T-cell malignancies. Cancer Biother Radiopharm. 19(4):391-8, 2004.
ROWAN W, TITE J, TOPLEY P, and BRETT S.J, Cross-linhing of the MabCampath antigen 5CD-52) mediates growth inhibition in human B-cell and T-lymphoma cell lines, and subsequent emergence of CD-52 deficient cells. Immunology 95: 427-436, 1998.
KEATING MJ, BYRD J, RAI K, FLINN I, JAIN V, BINET JL et all. Multicenter study of MabCampath in patients with chronic lymphocytic leukemia (B-cell) refractory to fludarabine. Blood 94 (suppl. 1): 705 A, 1999.